AURIXIN HC (Nova Pharmaceuticals Australasia Pty Ltd)
Product name
AURIXIN HC
Date registered
Evaluation commenced
Decision date
Approval time
150 (255 working days)
Active ingredients
ciprofloxacin hydrochloride, hydrocortisone
Registration type
New generic medicine
Indication
TRADENAME Ear Drops are indicated for the treatment of acute bacterial otitis externa, caused by organisms susceptible to ciprofloxacin (see Section 5.1 PHARMACODYNAMIC PROPERTIES), in adults and children aged 2 years and older.